Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

James W. Mier, M.D.


The research activities and funding listed below are automatically derived from NIH ExPORTER and other sources, which might result in incorrect or missing items. Faculty can login to make corrections and additions.
  1. P50CA101942 (MCDERMOTT, DAVID) Sep 18, 2003 - May 31, 2014
    DF/HCC Kidney Cancer SPORE
    Role: Co-Principal Investigator
  2. P50CA093683 (KUPPER, THOMAS S.) Sep 30, 2001 - Sep 29, 2010
    SPORE in Skin Cancer
    Role: Co-Principal Investigator
  3. R21CA092954 (MIER, JAMES W) Jun 18, 2001 - May 31, 2003
    Clinical Trials with IL12
    Role: Principal Investigator
  4. R21CA078055 (MIER, JAMES W) Sep 22, 1997 - Aug 31, 2000
    Role: Principal Investigator
  5. R01CA074401 (MIER, JAMES W) Apr 1, 1997 - Mar 31, 2000
    Role: Principal Investigator

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Thummalapalli R, Melms JC, Mier J, Izar B. Rapid evolution of acute kidney injury after initial infusion of pembrolizumab in a melanoma patient concurrently treated with RAF/MEK inhibitors. Melanoma Res. 2020 04; 30(2):219-222. PMID: 31634214.
  2. Makker V, Taylor MH, Aghajanian C, Oaknin A, Mier J, Cohn AL, Romeo M, Bratos R, Brose MS, DiSimone C, Messing M, Stepan DE, Dutcus CE, Wu J, Schmidt EV, Orlowski R, Sachdev P, Shumaker R, Casado Herraez A. Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer. J Clin Oncol. 2020 Sep 10; 38(26):2981-2992. PMID: 32167863.
  3. Saxena R, Wang Y, Mier JW. CXCR4 inhibition modulates the tumor microenvironment and retards the growth of B16-OVA melanoma and Renca tumors. Melanoma Res. 2020 02; 30(1):14-25. PMID: 31524789.
  4. Panka DJ, Wang W, Atkins MB, Mier JW. Retraction: The Raf Inhibitor BAY 43-9006 (Sorafenib) Induces Caspase-Independent Apoptosis in Melanoma Cells. Cancer Res. 2019 Oct 15; 79(20):5459. PMID: 31615813.
  5. Cho DC, Cohen MB, Panka DJ, Collins M, Ghebremichael M, Atkins MB, Signoretti S, Mier JW. Editor's Note: The Efficacy of the Novel Dual PI3-Kinase/mTOR Inhibitor NVP-BEZ235 Compared with Rapamycin in Renal Cell Carcinoma. Clin Cancer Res. 2019 Jul 01; 25(13):4194. PMID: 31263033.
  6. Mier JW. The tumor microenvironment in renal cell cancer. Curr Opin Oncol. 2019 05; 31(3):194-199. PMID: 30985497.
  7. Makker V, Rasco D, Vogelzang NJ, Brose MS, Cohn AL, Mier J, Di Simone C, Hyman DM, Stepan DE, Dutcus CE, Schmidt EV, Guo M, Sachdev P, Shumaker R, Aghajanian C, Taylor M. Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol. 2019 05; 20(5):711-718. PMID: 30922731.
  8. Leaf RK, Ferreri C, Rangachari D, Mier J, Witteles W, Ansstas G, Anagnostou T, Zubiri L, Piotrowska Z, Oo TH, Iberri D, Yarchoan M, Salama AKS, Johnson DB, Leavitt AD, Rahma OE, Reynolds KL, Leaf DE. Clinical and laboratory features of autoimmune hemolytic anemia associated with immune checkpoint inhibitors. Am J Hematol. 2019 05; 94(5):563-574. PMID: 30790338.
  9. Berry S, Giraldo N, Nguyen P, Green B, Xu H, Ogurtsova A, Soni A, Succaria F, Wang D, Roberts C, Stein J, Engle E, Pardoll D, Anders R, Cottrell T, Taube JM, Tran B, Voskoboynik M, Kuo J, Bang YL, Chung HC, Ahn MJ, Kim SW, Perera A, Freeman D, Achour I, Faggioni R, Xiao F, Ferte C, Lemech C, Meric-Bernstam F, Werner T, Hodi S, Messersmith W, Lewis N, Talluto C, Dostalek M, Tao A, McWhirter S, Trujillo D, Luke J, Xu C, Qi J, Qin G, Yu H, Jenkins M, Lo KM, Halle JP, Lan Y, Taylor M, Vogelzang N, Cohn A, Stepan D, Shumaker R, Dutcus C, Guo M, Schmidt E, Rasco D, Brose M, Vogelzang N, Di Simone C, Jain S, Richards D, Encarnacion C, Rasco D, Shumaker R, Dutcus C, Stepan D, Guo M, Schmidt E, Taylor M, Vogelzang N, Encarnacion C, Cohn A, Di Simone C, Rasco D, Richards D, Taylor M, Dutcus C, Stepan D, Shumaker R, Guo M, Schmidt E, Mier J, An J, Yang YY, Lee WH, Yang J, Kim JK, Kim HG, Paek SH, Lee JW, Woo J, Kim JB, Kwon H, Lim W, Paik NS, Kim YK, Moon BI, Janku F, Tan D, Martin-Liberal J, Takahashi S, Geva R, Gucalp A, Chen X, Subramanian K, Mataraza J, Wheler J, Bedard P. Correction to: 33rd Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2018). J Immunother Cancer. 2019 Feb 13; 7(1):46. PMID: 30760319.
  10. Melms JC, Ho KW, Thummalapalli R, Tyler J, Brinker TJ, Singh V, Sengupta S, Mier J, Izar B. Implementation of cell-free tumor DNA sequencing from the cerebrospinal fluid to guide treatment in a patient with primary leptomeningeal melanoma: A case report. Mol Clin Oncol. 2018 Jul; 9(1):58-61. PMID: 29977540.
  11. Sullivan RJ, Infante JR, Janku F, Wong DJL, Sosman JA, Keedy V, Patel MR, Shapiro GI, Mier JW, Tolcher AW, Wang-Gillam A, Sznol M, Flaherty K, Buchbinder E, Carvajal RD, Varghese AM, Lacouture ME, Ribas A, Patel SP, DeCrescenzo GA, Emery CM, Groover AL, Saha S, Varterasian M, Welsch DJ, Hyman DM, Li BT. First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study. Cancer Discov. 2018 02; 8(2):184-195. PMID: 29247021.
    Citations: 5     Fields:    
  12. Sarantopoulos J, Mita AC, He A, Wade JL, Hsueh CT, Morris JC, Lockhart AC, Quinn DI, Hwang J, Mier J, Zhang W, Wack C, Yin J, Clot PF, Rixe O. Safety and pharmacokinetics of cabazitaxel in patients with hepatic impairment: a phase I dose-escalation study. Cancer Chemother Pharmacol. 2017 Feb; 79(2):339-351. PMID: 28058445.
    Citations:    Fields:    Translation:HumansCTClinical Trials
  13. Erbe AK, Wang W, Goldberg J, Gallenberger M, Kim K, Carmichael L, Hess D, Mendonca EA, Song Y, Hank JA, Cheng SC, Signoretti S, Atkins M, Carlson A, Mier JW, Panka DJ, McDermott DF, Sondel PM. FCGR Polymorphisms Influence Response to IL2 in Metastatic Renal Cell Carcinoma. Clin Cancer Res. 2017 May 01; 23(9):2159-2168. PMID: 27742794.
    Citations: 1     Fields:    Translation:HumansCTClinical Trials
  14. Wang W, Erbe AK, Gallenberger M, Kim K, Carmichael L, Hess D, Mendonca EA, Song Y, Hank JA, Cheng SC, Signoretti S, Atkins M, Carlson A, Weiss JM, Mier J, Panka D, McDermott DF, Sondel PM. Killer immunoglobulin-like receptor (KIR) and KIR-ligand genotype do not correlate with clinical outcome of renal cell carcinoma patients receiving high-dose IL2. Cancer Immunol Immunother. 2016 12; 65(12):1523-1532. PMID: 27695964.
    Citations: 1     Fields:    Translation:Humans
  15. Wallin JJ, Bendell JC, Funke R, Sznol M, Korski K, Jones S, Hernandez G, Mier J, He X, Hodi FS, Denker M, Leveque V, Cañamero M, Babitski G, Koeppen H, Ziai J, Sharma N, Gaire F, Chen DS, Waterkamp D, Hegde PS, McDermott DF. Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma. Nat Commun. 2016 08 30; 7:12624. PMID: 27571927.
    Citations: 30     Fields:    Translation:HumansCellsCTClinical Trials
  16. van der Mijn JC, Panka DJ, Geissler AK, Verheul HM, Mier JW. Novel drugs that target the metabolic reprogramming in renal cell cancer. Cancer Metab. 2016; 4:14. PMID: 27418963.
    Citations: 9     
  17. Wang X, Solban N, Khanna P, Callea M, Song J, Alsop DC, Pearsall RS, Atkins MB, Mier JW, Signoretti S, Alimzhanov M, Kumar R, Bhasin MK, Bhatt RS. Inhibition of ALK1 signaling with dalantercept combined with VEGFR TKI leads to tumor stasis in renal cell carcinoma. Oncotarget. 2016 Jul 05; 7(27):41857-41869. PMID: 27248821.
    Citations: 4     Fields:    Translation:HumansAnimalsCells
  18. van der Mijn JC, Broxterman HJ, Knol JC, Piersma SR, De Haas RR, Dekker H, Pham TV, Van Beusechem VW, Halmos B, Mier JW, Jiménez CR, Verheul HM. Sunitinib activates Axl signaling in renal cell cancer. Int J Cancer. 2016 Jun 15; 138(12):3002-10. PMID: 26815723.
    Citations: 2     Fields:    Translation:HumansCells
  19. Sullivan RJ, Ibrahim N, Lawrence DP, Aldridge J, Giobbie-Hurder A, Hodi FS, Flaherty KT, Conley C, Mier JW, Atkins MB, McDermott DF. A Phase I Trial of Bortezomib and Sorafenib in Advanced Malignant Melanoma. Oncologist. 2015 Jun; 20(6):617-8. PMID: 25986244.
    Citations: 2     Fields:    Translation:HumansCTClinical Trials
  20. Mier JW. Immune checkpoint inhibitors in the treatment of metastatic melanoma. Clin Ther. 2015 Apr 01; 37(4):753-4. PMID: 25726456.
    Citations:    Fields:    
  21. Zhang L, Wang X, Bullock AJ, Callea M, Shah H, Song J, Moreno K, Visentin B, Deutschman D, Alsop DC, Atkins MB, Mier JW, Signoretti S, Bhasin M, Sabbadini RA, Bhatt RS. Anti-S1P Antibody as a Novel Therapeutic Strategy for VEGFR TKI-Resistant Renal Cancer. Clin Cancer Res. 2015 Apr 15; 21(8):1925-1934. PMID: 25589614.
    Citations: 17     Fields:    Translation:HumansAnimalsCells
  22. McDermott DF, Cheng SC, Signoretti S, Margolin KA, Clark JI, Sosman JA, Dutcher JP, Logan TF, Curti BD, Ernstoff MS, Appleman L, Wong MK, Khushalani NI, Oleksowicz L, Vaishampayan UN, Mier JW, Panka DJ, Bhatt RS, Bailey AS, Leibovich BC, Kwon ED, Kabbinavar FF, Belldegrun AS, Figlin RA, Pantuck AJ, Regan MM, Atkins MB. The high-dose aldesleukin "select" trial: a trial to prospectively validate predictive models of response to treatment in patients with metastatic renal cell carcinoma. Clin Cancer Res. 2015 Feb 01; 21(3):561-8. PMID: 25424850.
    Citations: 25     Fields:    Translation:HumansCTClinical Trials
  23. Panka DJ, Buchbinder E, Giobbie-Hurder A, Schalck AP, Montaser-Kouhsari L, Sepehr A, Lawrence DP, McDermott DF, Cohen R, Carlson A, Wargo JA, Merritt R, Seery VJ, Hodi FS, Gunturi A, Fredrick D, Atkins MB, Iafrate AJ, Flaherty KT, Mier JW, Sullivan RJ. Clinical utility of a blood-based BRAF(V600E) mutation assay in melanoma. Mol Cancer Ther. 2014 Dec; 13(12):3210-8. PMID: 25319388.
    Citations: 8     Fields:    Translation:HumansCells
  24. van der Mijn JC, Mier JW, Broxterman HJ, Verheul HM. Predictive biomarkers in renal cell cancer: insights in drug resistance mechanisms. Drug Resist Updat. 2014 Oct-Dec; 17(4-6):77-88. PMID: 25457974.
    Citations: 11     Fields:    Translation:Humans
  25. Frederick DT, Salas Fragomeni RA, Schalck A, Ferreiro-Neira I, Hoff T, Cooper ZA, Haq R, Panka DJ, Kwong LN, Davies MA, Cusack JC, Flaherty KT, Fisher DE, Mier JW, Wargo JA, Sullivan RJ. Clinical profiling of BCL-2 family members in the setting of BRAF inhibition offers a rationale for targeting de novo resistance using BH3 mimetics. PLoS One. 2014; 9(7):e101286. PMID: 24983357.
    Citations: 12     Fields:    Translation:HumansAnimalsCellsCTClinical Trials
  26. Wang X, Bullock AJ, Zhang L, Wei L, Yu D, Mahagaokar K, Alsop DC, Mier JW, Atkins MB, Coxon A, Oliner J, Bhatt RS. The role of angiopoietins as potential therapeutic targets in renal cell carcinoma. Transl Oncol. 2014 Apr; 7(2):188-95. PMID: 24704536.
    Citations: 7     
  27. Panka DJ, Mier JW, Sullivan RJ. Assaying for BRAF V600E in tissue and blood in melanoma. Methods Mol Biol. 2014; 1102:117-36. PMID: 24258977.
    Citations: 3     Fields:    Translation:HumansCells
  28. Panka DJ, Liu Q, Geissler AK, Mier JW. Effects of HDM2 antagonism on sunitinib resistance, p53 activation, SDF-1 induction, and tumor infiltration by CD11b+/Gr-1+ myeloid derived suppressor cells. Mol Cancer. 2013 Mar 05; 12:17. PMID: 23497256.
    Citations: 12     Fields:    Translation:HumansAnimalsCells
  29. Wang X, Solban N, Wei L, Signoretti S, Alsop D, Alimzhanov M, Pearsall S, Atkins MB, Kumar R, Sherman ML, Mier JW. Inhibition of tumor growth in a VEGFR TKI-resistant model of renal cell carcinoma using dalantercept combined with sunitinib. J Clin Oncol. 2013 Feb 20; 31(6_suppl):370. PMID: 28136892.
  30. Zhu S, Cohen MB, Bjorge JD, Mier JW, Cho DC. PI3K inhibition potentiates Bcl-2-dependent apoptosis in renal carcinoma cells. J Cell Mol Med. 2013 Mar; 17(3):377-85. PMID: 23387989.
    Citations: 2     Fields:    Translation:HumansCells
  31. Cho DC, Mier JW. Dual inhibition of PI3-kinase and mTOR in renal cell carcinoma. Curr Cancer Drug Targets. 2013 Feb; 13(2):126-42. PMID: 23259857.
    Citations: 7     Fields:    Translation:HumansCells
  32. Wang X, Zhang L, O'Neill A, Bahamon B, Alsop DC, Mier JW, Goldberg SN, Signoretti S, Atkins MB, Wood CG, Bhatt RS. Cox-2 inhibition enhances the activity of sunitinib in human renal cell carcinoma xenografts. Br J Cancer. 2013 Feb 05; 108(2):319-26. PMID: 23322198.
    Citations: 14     Fields:    Translation:HumansAnimalsCells
  33. Hong DS, Kurzrock R, Supko JG, He X, Naing A, Wheler J, Lawrence D, Eder JP, Meyer CJ, Ferguson DA, Mier J, Konopleva M, Konoplev S, Andreeff M, Kufe D, Lazarus H, Shapiro GI, Dezube BJ. A phase I first-in-human trial of bardoxolone methyl in patients with advanced solid tumors and lymphomas. Clin Cancer Res. 2012 Jun 15; 18(12):3396-406. PMID: 22634319.
    Citations: 48     Fields:    Translation:HumansCTClinical Trials
  34. Wang X, Zhang L, Goldberg SN, Bhasin M, Brown V, Alsop DC, Signoretti S, Mier JW, Atkins MB, Bhatt RS. High dose intermittent sorafenib shows improved efficacy over conventional continuous dose in renal cell carcinoma. J Transl Med. 2011 Dec 21; 9:220. PMID: 22188900.
    Citations: 8     Fields:    Translation:HumansAnimalsCells
  35. Liu Q, Mier JW, Panka DJ. Differential modulatory effects of GSK-3ß and HDM2 on sorafenib-induced AIF nuclear translocation (programmed necrosis) in melanoma. Mol Cancer. 2011 Sep 19; 10:115. PMID: 21929745.
    Citations: 4     Fields:    Translation:HumansAnimalsCells
  36. Zhang L, Bhasin M, Schor-Bardach R, Wang X, Collins MP, Panka D, Putheti P, Signoretti S, Alsop DC, Libermann T, Atkins MB, Mier JW, Goldberg SN, Bhatt RS. Resistance of renal cell carcinoma to sorafenib is mediated by potentially reversible gene expression. PLoS One. 2011 Apr 29; 6(4):e19144. PMID: 21559452.
    Citations: 27     Fields:    Translation:HumansAnimalsCells
  37. Leal TB, Remick SC, Takimoto CH, Ramanathan RK, Davies A, Egorin MJ, Hamilton A, LoRusso PA, Shibata S, Lenz HJ, Mier J, Sarantopoulos J, Mani S, Wright JJ, Ivy SP, Neuwirth R, von Moltke L, Venkatakrishnan K, Mulkerin D. Dose-escalating and pharmacological study of bortezomib in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group Study. Cancer Chemother Pharmacol. 2011 Dec; 68(6):1439-47. PMID: 21479634.
    Citations: 14     Fields:    Translation:Humans
  38. Pandya SS, Mier JW, McDermott DF, Cho DC. Addition of gemcitabine at the time of sunitinib resistance in metastatic renal cell cancer. BJU Int. 2011 Oct; 108(8 Pt 2):E245-9. PMID: 21320274.
    Citations: 4     Fields:    Translation:Humans
  39. Panka DJ, Sullivan RJ, Mier JW. An inexpensive, specific and highly sensitive protocol to detect the BrafV600E mutation in melanoma tumor biopsies and blood. Melanoma Res. 2010 Oct; 20(5):401-7. PMID: 20679909.
    Citations: 7     Fields:    Translation:HumansCells
  40. Bhatt RS, Wang X, Zhang L, Collins MP, Signoretti S, Alsop DC, Goldberg SN, Atkins MB, Mier JW. Renal cancer resistance to antiangiogenic therapy is delayed by restoration of angiostatic signaling. Mol Cancer Ther. 2010 Oct; 9(10):2793-802. PMID: 20699227.
    Citations: 20     Fields:    Translation:HumansAnimalsCells
  41. Cho DC, Cohen MB, Panka DJ, Collins M, Ghebremichael M, Atkins MB, Signoretti S, Mier JW. The efficacy of the novel dual PI3-kinase/mTOR inhibitor NVP-BEZ235 compared with rapamycin in renal cell carcinoma. Clin Cancer Res. 2010 Jul 15; 16(14):3628-38. PMID: 20606035.
    Citations: 82     Fields:    Translation:HumansAnimalsCells
  42. Cho DC, Figlin RA, Flaherty KT, Michaelson D, Sosman JA, Ghebremichael M, Bowers ME, Mier JW, Atkins MB, McDermott DF. A phase II trial of perifosine in patients with advanced renal cell carcinoma (RCC) who have failed tyrosine kinase inhibitors (TKI). J Clin Oncol. 2009 May 20; 27(15_suppl):5101. PMID: 27964377.
  43. Atkins MB, Bukowski RM, Escudier BJ, Figlin RA, Hudes GH, Kaelin WG, Linehan WM, McDermott DF, Mier JW, Pedrosa I, Rini BI, Signoretti S, Sosman JA, Teh BT, Wood CG, Zurita AJ, King L. Innovations and challenges in renal cancer: summary statement from the Third Cambridge Conference. Cancer. 2009 May 15; 115(10 Suppl):2247-51. PMID: 19402064.
    Citations: 8     Fields:    Translation:Humans
  44. Cho DC, Puzanov I, Regan MM, Schwarzberg T, Seery V, Lee MY, Liu V, Bhatt R, Koon H, Mier JW, Sosman JA, Atkins MB, McDermott DF. Retrospective analysis of the safety and efficacy of interleukin-2 after prior VEGF-targeted therapy in patients with advanced renal cell carcinoma. J Immunother. 2009 Feb-Mar; 32(2):181-5. PMID: 19238017.
    Citations: 12     Fields:    Translation:Humans
  45. Schwarzberg T, Regan MM, Liu V, Mier JW, Cho D, Koon H, Bhatt RS, Seery V, Bradley K, Atkins MB, McDermott DF. Retrospective analysis of interleukin-2 therapy in patients with metastatic renal cell carcinoma who had received prior antiangiogenic therapy. J Clin Oncol. 2008 May 20; 26(15_suppl):5044. PMID: 27948868.
  46. Hong DS, Kurzrock R, Supko JG, Lawrence DP, Wheler JJ, Meyer CJ, Mier JW, Andreeff M, Shapiro GI, Dezube BJ. Phase I trial with a novel oral NF-?B/STAT3 inhibitor RTA 402 in patients with solid tumors and lymphoid malignancies. J Clin Oncol. 2008 May 20; 26(15_suppl):3517. PMID: 27949759.
  47. Lenahan C, Cho D, Bissonnette A, Rosenblatt J, Wu Z, Freeman G, Mier JW, Kufe D, Atkins MB, Avigan D. Immunologic effects of sunitinib in renal cell carcinoma. J Clin Oncol. 2008 May 20; 26(15_suppl):14551. PMID: 27949992.
  48. Sosman JA, Carrillo C, Urba WJ, Flaherty L, Atkins MB, Clark JI, Dutcher J, Margolin KA, Mier J, Gollob J, Kirkwood JM, Panka DJ, Crosby NA, O'Boyle K, LaFleur B, Ernstoff MS. Three phase II cytokine working group trials of gp100 (210M) peptide plus high-dose interleukin-2 in patients with HLA-A2-positive advanced melanoma. J Clin Oncol. 2008 May 10; 26(14):2292-8. PMID: 18467720.
    Citations: 32     Fields:    Translation:HumansCTClinical Trials
  49. Negin B, Panka D, Wang W, Siddiqui M, Tawa N, Mullen J, Tahan S, Mandato L, Polivy A, Mier J, Atkins M. Effect of melanoma on immune function in the regional lymph node basin. Clin Cancer Res. 2008 Feb 01; 14(3):654-9. PMID: 18245524.
    Citations: 1     Fields:    Translation:Humans
  50. Panka DJ, Cho DC, Atkins MB, Mier JW. GSK-3beta inhibition enhances sorafenib-induced apoptosis in melanoma cell lines. J Biol Chem. 2008 Jan 11; 283(2):726-32. PMID: 17991738.
    Citations: 25     Fields:    Translation:HumansCells
  51. Cho D, Signoretti S, Regan M, Mier JW, Atkins MB. The role of mammalian target of rapamycin inhibitors in the treatment of advanced renal cancer. Clin Cancer Res. 2007 Jan 15; 13(2 Pt 2):758s-763s. PMID: 17255306.
    Citations: 39     Fields:    Translation:Humans
  52. Robertson MJ, Mier JW, Logan T, Atkins M, Koon H, Koch KM, Kathman S, Pandite LN, Oei C, Kirby LC, Jewell RC, Bell WN, Thurmond LM, Weisenbach J, Roberts S, Dar MM. Clinical and biological effects of recombinant human interleukin-18 administered by intravenous infusion to patients with advanced cancer. Clin Cancer Res. 2006 Jul 15; 12(14 Pt 1):4265-73. PMID: 16857801.
    Citations: 28     Fields:    Translation:HumansCTClinical Trials
  53. Negin BP, Panka D, Wang W, Tawa N, Mullen J, Tahan S, Mandato L, Polivy A, Mier J, Atkins M. Effect of melanoma on immune function in regional lymph nodes (LN). J Clin Oncol. 2006 Jun 20; 24(18_suppl):8000. PMID: 27955566.
  54. McDermott DF, Cho DC, Merchan JR, Bhatt RS, Seery V, Mosher JL, Farquhar MB, Mier JW, Atkins MB, Sukhatme VP. A phase II pilot trial of low dose, continuous infusion, or "metronomic", paclitaxel and oral celecoxib in patients with metastatic melanoma. J Clin Oncol. 2006 Jun 20; 24(18_suppl):8010. PMID: 27955581.
  55. Atkins MB, Elder DE, Essner R, Flaherty KT, Gajewski TF, Haluska FG, Hwu P, Keilholz U, Kirkwood JM, Mier JW, Ross MI, Slingluff CL, Sondak VK, Sosman JA, Weinstock MA, King L. Innovations and challenges in melanoma: summary statement from the first Cambridge conference. Clin Cancer Res. 2006 Apr 01; 12(7 Pt 2):2291s-2296s. PMID: 16609047.
    Citations:    Fields:    Translation:Humans
  56. Panka DJ, Atkins MB, Mier JW. Targeting the mitogen-activated protein kinase pathway in the treatment of malignant melanoma. Clin Cancer Res. 2006 Apr 01; 12(7 Pt 2):2371s-2375s. PMID: 16609061.
    Citations: 31     Fields:    Translation:HumansAnimals
  57. Panka DJ, Wang W, Atkins MB, Mier JW. The Raf inhibitor BAY 43-9006 (Sorafenib) induces caspase-independent apoptosis in melanoma cells. Cancer Res. 2006 Feb 01; 66(3):1611-9. PMID: 16452220.
    Citations: 46     Fields:    Translation:HumansCells
  58. Atkins M, Regan M, McDermott D, Mier J, Stanbridge E, Youmans A, Febbo P, Upton M, Lechpammer M, Signoretti S. Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer. Clin Cancer Res. 2005 May 15; 11(10):3714-21. PMID: 15897568.
    Citations: 102     Fields:    Translation:Humans
  59. Zea AH, Rodriguez PC, Atkins MB, Hernandez C, Signoretti S, Zabaleta J, McDermott D, Quiceno D, Youmans A, O'Neill A, Mier J, Ochoa AC. Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion. Cancer Res. 2005 Apr 15; 65(8):3044-8. PMID: 15833831.
    Citations: 264     Fields:    Translation:HumansCells
  60. McDermott DF, Regan MM, Clark JI, Flaherty LE, Weiss GR, Logan TF, Kirkwood JM, Gordon MS, Sosman JA, Ernstoff MS, Tretter CP, Urba WJ, Smith JW, Margolin KA, Mier JW, Gollob JA, Dutcher JP, Atkins MB. Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol. 2005 Jan 01; 23(1):133-41. PMID: 15625368.
    Citations: 146     Fields:    Translation:HumansCTClinical Trials
  61. Avigan D, Vasir B, Gong J, Borges V, Wu Z, Uhl L, Atkins M, Mier J, McDermott D, Smith T, Giallambardo N, Stone C, Schadt K, Dolgoff J, Tetreault JC, Villarroel M, Kufe D. Fusion cell vaccination of patients with metastatic breast and renal cancer induces immunological and clinical responses. Clin Cancer Res. 2004 Jul 15; 10(14):4699-708. PMID: 15269142.
    Citations: 40     Fields:    Translation:HumansCellsPHPublic HealthCTClinical Trials
  62. Famoyin C, Byrnes C, Roberts S, Gollob J, Atkins M, Mier J, Ko YJ, Gautam S, McDemott D. A randomized phase II study of thalidomide with or without erythropoietin (EPO) in metastatic renal cell carcinoma (RCC). J Clin Oncol. 2004 Jul 15; 22(14_suppl):4747. PMID: 28017011.
  63. Robertson MJ, Mier J, Logan T, Koon H, Weisenbach J, Roberts S, Oei C, Kirby L, Kathman S, Pandite L. Tolerability and anti-tumor activity of recombinant human IL-18 (rhIL-18) administered as five daily intravenous infusions in patients with solid tumors. J Clin Oncol. 2004 Jul 15; 22(14_suppl):2553. PMID: 28015258.
  64. Panka DJ, Mier JW. Canstatin inhibits Akt activation and induces Fas-dependent apoptosis in endothelial cells. J Biol Chem. 2003 Sep 26; 278(39):37632-6. PMID: 12876280.
    Citations: 28     Fields:    Translation:HumansCells
  65. Gollob JA, Veenstra KG, Parker RA, Mier JW, McDermott DF, Clancy D, Tutin L, Koon H, Atkins MB. Phase I trial of concurrent twice-weekly recombinant human interleukin-12 plus low-dose IL-2 in patients with melanoma or renal cell carcinoma. J Clin Oncol. 2003 Jul 01; 21(13):2564-73. PMID: 12829677.
    Citations: 19     Fields:    Translation:HumansCTClinical Trials
  66. Sosman JA, Mier JW. Biological drug duo delivers one-two tumor punch. Nat Med. 2003 Jun; 9(6):649-50. PMID: 12778160.
    Citations: 1     Fields:    Translation:HumansAnimals
  67. Mier JW. Immunotherapy With Low-Dose IL-2 in Combination With GM-CSF. J Immunother. 2003 Mar-Apr; 26(2):95-6. PMID: 12616100.
    Citations:    Fields:    Translation:Humans
  68. Janssen RA, Kim PN, Mier JW, Morrison DK. Overexpression of kinase suppressor of Ras upregulates the high-molecular-weight tropomyosin isoforms in ras-transformed NIH 3T3 fibroblasts. Mol Cell Biol. 2003 Mar; 23(5):1786-97. PMID: 12588996.
    Citations: 10     Fields:    Translation:AnimalsCells
  69. Atkins MB, Gollob JA, Sosman JA, McDermott DF, Tutin L, Sorokin P, Parker RA, Mier JW. A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, temozolomide, interleukin 2, and IFN-alpha 2B in patients with metastatic melanoma. Clin Cancer Res. 2002 Oct; 8(10):3075-81. PMID: 12374674.
    Citations: 11     Fields:    Translation:HumansCTClinical Trials
  70. Kaser A, Brandacher G, Steurer W, Kaser S, Offner FA, Zoller H, Theurl I, Widder W, Molnar C, Ludwiczek O, Atkins MB, Mier JW, Tilg H. Interleukin-6 stimulates thrombopoiesis through thrombopoietin: role in inflammatory thrombocytosis. Blood. 2001 Nov 01; 98(9):2720-5. PMID: 11675343.
    Citations: 99     Fields:    Translation:HumansAnimalsCells
  71. Kim PN, Jonasch E, Mosterman BC, Mier JW, Janssen RA. Radicicol suppresses transformation and restores tropomyosin-2 expression in both ras- and MEK-transformed cells without inhibiting the Raf/MEK/ERK signaling cascade. Cell Growth Differ. 2001 Nov; 12(11):543-50. PMID: 11714635.
    Citations: 1     Fields:    Translation:AnimalsCells
  72. Flaherty LE, Atkins M, Sosman J, Weiss G, Clark JI, Margolin K, Dutcher J, Gordon MS, Lotze M, Mier J, Sorokin P, Fisher RI, Appel C, Du W. Outpatient biochemotherapy with interleukin-2 and interferon alfa-2b in patients with metastatic malignant melanoma: results of two phase II cytokine working group trials. J Clin Oncol. 2001 Jul 01; 19(13):3194-202. PMID: 11432886.
    Citations: 9     Fields:    Translation:HumansCTClinical Trials
  73. Atkins MB, Redman B, Mier J, Gollob J, Weber J, Sosman J, MacPherson BL, Plasse T. A phase I study of CNI-1493, an inhibitor of cytokine release, in combination with high-dose interleukin-2 in patients with renal cancer and melanoma. Clin Cancer Res. 2001 Mar; 7(3):486-92. PMID: 11297238.
    Citations: 12     Fields:    Translation:HumansCTClinical Trials
  74. Panka DJ, Mano T, Suhara T, Walsh K, Mier JW. Phosphatidylinositol 3-kinase/Akt activity regulates c-FLIP expression in tumor cells. J Biol Chem. 2001 Mar 09; 276(10):6893-6. PMID: 11145953.
    Citations: 52     Fields:    Translation:HumansCells
  75. Gollob JA, Mier JW, Atkins MB. Clinical use of systemic IL-12 therapy. Cancer Chemother Biol Response Modif. 2001; 19:353-69. PMID: 11686023.
    Citations: 4     Fields:    Translation:Humans
  76. Gollob JA, Veenstra KG, Mier JW, Atkins MB. Agranulocytosis and hemolytic anemia in patients with renal cell cancer treated with interleukin-12. J Immunother. 2001 Jan-Feb; 24(1):91-8. PMID: 11211153.
    Citations: 4     Fields:    Translation:HumansCTClinical Trials
  77. Dutcher J, Atkins MB, Margolin K, Weiss G, Clark J, Sosman J, Logan T, Aronson F, Mier J. Kidney cancer: the Cytokine Working Group experience (1986-2001): part II. Management of IL-2 toxicity and studies with other cytokines. Med Oncol. 2001; 18(3):209-19. PMID: 11917945.
    Citations: 14     Fields:    Translation:Humans
  78. Atkins MB, Dutcher J, Weiss G, Margolin K, Clark J, Sosman J, Logan T, Aronson F, Mier J. Kidney cancer: the Cytokine Working Group experience (1986-2001): part I. IL-2-based clinical trials. Med Oncol. 2001; 18(3):197-207. PMID: 11917944.
    Citations: 3     Fields:    Translation:HumansCells
  79. Gollob JA, Veenstra KG, Jyonouchi H, Kelly AM, Ferrieri P, Panka DJ, Altare F, Fieschi C, Casanova JL, Frank DA, Mier JW. Impairment of STAT activation by IL-12 in a patient with atypical mycobacterial and staphylococcal infections. J Immunol. 2000 Oct 01; 165(7):4120-6. PMID: 11034424.
    Citations: 8     Fields:    Translation:HumansCells
  80. Dutcher JP, Logan T, Gordon M, Sosman J, Weiss G, Margolin K, Plasse T, Mier J, Lotze M, Clark J, Atkins M. Phase II trial of interleukin 2, interferon alpha, and 5-fluorouracil in metastatic renal cell cancer: a cytokine working group study. Clin Cancer Res. 2000 Sep; 6(9):3442-50. PMID: 10999727.
    Citations: 11     Fields:    Translation:HumansCTClinical Trials
  81. McDermott DF, Mier JW, Lawrence DP, van den Brink MR, Clancy MA, Rubin KM, Atkins MB. A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin 2, and interferon alpha-2B in patients with metastatic melanoma. Clin Cancer Res. 2000 Jun; 6(6):2201-8. PMID: 10873069.
    Citations: 12     Fields:    Translation:HumansCTClinical Trials
  82. Gollob JA, Mier JW, Veenstra K, McDermott DF, Clancy D, Clancy M, Atkins MB. Phase I trial of twice-weekly intravenous interleukin 12 in patients with metastatic renal cell cancer or malignant melanoma: ability to maintain IFN-gamma induction is associated with clinical response. Clin Cancer Res. 2000 May; 6(5):1678-92. PMID: 10815886.
    Citations: 55     Fields:    Translation:HumansCTClinical Trials
  83. Kamphaus GD, Colorado PC, Panka DJ, Hopfer H, Ramchandran R, Torre A, Maeshima Y, Mier JW, Sukhatme VP, Kalluri R. Canstatin, a novel matrix-derived inhibitor of angiogenesis and tumor growth. J Biol Chem. 2000 Jan 14; 275(2):1209-15. PMID: 10625665.
    Citations: 101     Fields:    Translation:HumansAnimalsCells
  84. Jasuja RR, Mier JW. Differential effects of hydroxamate inhibitors on PMA and ligand-induced L-Selectin down-modulation: role of membrane proximal and cytoplasmic domains. Int J Immunopathol Pharmacol. 2000 Jan-Apr; 13(1):1-12. PMID: 12749772.
    Citations: 2     Fields:    
  85. Vannier E, Kaser A, Atkins MB, Fantuzzi G, Dinarello CA, Mier JW, Tilg H. Elevated circulating levels of soluble interleukin-1 receptor type II during interleukin-2 immunotherapy. Eur Cytokine Netw. 1999 Mar; 10(1):37-42. PMID: 10210771.
    Citations: 3     Fields:    Translation:HumansCTClinical Trials
  86. Janssen RA, Veenstra KG, Jonasch P, Jonasch E, Mier JW. Ras- and Raf-induced down-modulation of non-muscle tropomyosin are MEK-independent. J Biol Chem. 1998 Nov 27; 273(48):32182-6. PMID: 9822696.
    Citations: 7     Fields:    Translation:AnimalsCells
  87. Potter DA, Tirnauer JS, Janssen R, Croall DE, Hughes CN, Fiacco KA, Mier JW, Maki M, Herman IM. Calpain regulates actin remodeling during cell spreading. J Cell Biol. 1998 May 04; 141(3):647-62. PMID: 9566966.
    Citations: 61     Fields:    Translation:HumansAnimalsCells
  88. McDermott DF, Trehu EG, Mier JW, Sorce D, Rand W, Ronayne L, Kappler K, Clancy M, Klempner M, Atkins MB. A two-part phase I trial of high-dose interleukin 2 in combination with soluble (Chinese hamster ovary) interleukin 1 receptor. Clin Cancer Res. 1998 May; 4(5):1203-13. PMID: 9607578.
    Citations: 1     Fields:    Translation:HumansAnimalsCellsCTClinical Trials
  89. Dutcher JP, Atkins M, Fisher R, Weiss G, Margolin K, Aronson F, Sosman J, Lotze M, Gordon M, Logan T, Mier J. Interleukin-2-based therapy for metastatic renal cell cancer: the Cytokine Working Group experience, 1989-1997. Cancer J Sci Am. 1997 Dec; 3 Suppl 1:S73-8. PMID: 9457399.
    Citations: 10     Fields:    Translation:HumansCTClinical Trials
  90. Janssen RA, Mier JW. Tropomyosin-2 cDNA lacking the 3' untranslated region riboregulator induces growth inhibition of v-Ki-ras-transformed fibroblasts. Mol Biol Cell. 1997 May; 8(5):897-908. PMID: 9168473.
    Citations: 7     Fields:    Translation:AnimalsCells
  91. Dutcher JP, Fisher RI, Weiss G, Aronson F, Margolin K, Louie A, Mier J, Caliendo G, Sosman JA, Eckardt JR, Ernest ML, Doroshow J, Atkins M. Outpatient subcutaneous interleukin-2 and interferon-alpha for metastatic renal cell cancer: five-year follow-up of the Cytokine Working Group Study. Cancer J Sci Am. 1997 May-Jun; 3(3):157-62. PMID: 9161781.
    Citations: 14     Fields:    Translation:HumansCTClinical Trials
  92. Margolin K, Atkins M, Sparano J, Sosman J, Weiss G, Lotze M, Doroshow J, Mier J, O'Boyle K, Fisher R, Campbell E, Rubin J, Federighi D, Bursten S. Prospective randomized trial of lisofylline for the prevention of toxicities of high-dose interleukin 2 therapy in advanced renal cancer and malignant melanoma. Clin Cancer Res. 1997 Apr; 3(4):565-72. PMID: 9815721.
    Citations: 5     Fields:    Translation:HumansCTClinical Trials
  93. Du Bois JS, Trehu EG, Mier JW, Shapiro L, Epstein M, Klempner M, Dinarello C, Kappler K, Ronayne L, Rand W, Atkins MB. Randomized placebo-controlled clinical trial of high-dose interleukin-2 in combination with a soluble p75 tumor necrosis factor receptor immunoglobulin G chimera in patients with advanced melanoma and renal cell carcinoma. J Clin Oncol. 1997 Mar; 15(3):1052-62. PMID: 9060545.
    Citations: 4     Fields:    Translation:HumansCellsCTClinical Trials
  94. Atkins MB, Robertson MJ, Gordon M, Lotze MT, DeCoste M, DuBois JS, Ritz J, Sandler AB, Edington HD, Garzone PD, Mier JW, Canning CM, Battiato L, Tahara H, Sherman ML. Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies. Clin Cancer Res. 1997 Mar; 3(3):409-17. PMID: 9815699.
    Citations: 89     Fields:    Translation:HumansCTClinical Trials
  95. Mier J, León EL, Castillo A, Robledo F, Blanco R. Early versus late necrosectomy in severe necrotizing pancreatitis. Am J Surg. 1997 Feb; 173(2):71-5. PMID: 9074366.
    Citations: 91     Fields:    Translation:HumansCTClinical Trials
  96. Sosman JA, Aronson FR, Sznol M, Atkins MB, Dutcher JP, Weiss GR, Isaacs RE, Margolin KA, Fisher RI, Ernest ML, Mier J, Oleksowicz L, Eckhardt JR, Levitt D, Doroshow JH. Concurrent phase I trials of intravenous interleukin 6 in solid tumor patients: reversible dose-limiting neurological toxicity. Clin Cancer Res. 1997 Jan; 3(1):39-46. PMID: 9815535.
    Citations: 6     Fields:    Translation:HumansCellsCTClinical Trials
  97. Stoddart JH, Jasuja RR, Sikorski MA, von Andrian UH, Mier JW. Protease-resistant L-selectin mutants. Down-modulation by cross-linking but not cellular activation. J Immunol. 1996 Dec 15; 157(12):5653-9. PMID: 8955218.
    Citations: 3     Fields:    Translation:HumansCells
  98. Sikorski MA, Staunton DE, Mier JW. L-selectin crosslinking induces integrin-dependent adhesion: evidence for a signaling pathway involving PTK but not PKC. Cell Adhes Commun. 1996 Nov; 4(4-5):355-67. PMID: 9117353.
    Citations: 2     Fields:    Translation:HumansCells
  99. Trehu EG, Mier JW, Dubois JS, Sorce D, Klempner MS, Epstein M, Dinarello CA, Shapiro L, Kappler K, Ronayne L, Atkins MB. Phase I trial of interleukin 2 in combination with the soluble tumor necrosis factor receptor p75 IgG chimera. Clin Cancer Res. 1996 Aug; 2(8):1341-51. PMID: 9816306.
    Citations: 2     Fields:    Translation:HumansCTClinical Trials
  100. Ryan CM, Atkins MB, Mier JW, Gelfand JA, Tompkins RG. Effects of malignancy and interleukin-2 infusion on gut macromolecular permeability. Crit Care Med. 1995 Nov; 23(11):1801-6. PMID: 7587254.
    Citations: 2     Fields:    Translation:HumansCTClinical Trials
  101. Tilg H, Atkins MB, Dinarello CA, Mier JW. Induction of circulating interleukin 10 by interleukin 1 and interleukin 2, but not interleukin 6 immunotherapy. Cytokine. 1995 Oct; 7(7):734-9. PMID: 8580384.
    Citations: 3     Fields:    Translation:HumansCellsCTClinical Trials
  102. Atkins MB, Kappler K, Mier JW, Isaacs RE, Berkman EM. Interleukin-6-associated anemia: determination of the underlying mechanism. Blood. 1995 Aug 15; 86(4):1288-91. PMID: 7632934.
    Citations: 4     Fields:    Translation:HumansCTClinical Trials
  103. Atkins MB, O'Boyle KR, Sosman JA, Weiss GR, Margolin KA, Ernest ML, Kappler K, Mier JW, Sparano JA, Fisher RI, et al. Multiinstitutional phase II trial of intensive combination chemoimmunotherapy for metastatic melanoma. J Clin Oncol. 1994 Aug; 12(8):1553-60. PMID: 8040667.
    Citations: 15     Fields:    Translation:HumansCTClinical Trials
  104. Tilg H, Shapiro L, Vannier E, Poutsiaka DD, Trehu E, Atkins MB, Dinarello CA, Mier JW. Induction of circulating antagonists to IL-1 and TNF by IL-2 administration and their effects on IL-2 induced cytokine production in vitro. J Immunol. 1994 Mar 15; 152(6):3189-98. PMID: 8144913.
    Citations: 3     Fields:    Translation:HumansCells
  105. Tilg H, Trehu E, Shapiro L, Pape D, Atkins MB, Dinarello CA, Mier JW. Induction of circulating soluble tumour necrosis factor receptor and interleukin 1 receptor antagonist following interleukin 1 alpha infusion in humans. Cytokine. 1994 Mar; 6(2):215-9. PMID: 8032003.
    Citations: 2     Fields:    Translation:HumansCTClinical Trials
  106. Margolin K, Aronson FR, Sznol M, Atkins MB, Gucalp R, Fisher RI, Sunderland M, Doroshow JH, Ernest ML, Mier JW, et al. Phase II studies of recombinant human interleukin-4 in advanced renal cancer and malignant melanoma. J Immunother Emphasis Tumor Immunol. 1994 Feb; 15(2):147-53. PMID: 8136948.
    Citations: 8     Fields:    Translation:HumansCTClinical Trials
  107. Tilg H, Trehu E, Atkins MB, Dinarello CA, Mier JW. Interleukin-6 (IL-6) as an anti-inflammatory cytokine: induction of circulating IL-1 receptor antagonist and soluble tumor necrosis factor receptor p55. Blood. 1994 Jan 01; 83(1):113-8. PMID: 8274730.
    Citations: 164     Fields:    Translation:HumansCellsCTClinical Trials
  108. Granowitz EV, Porat R, Mier JW, Orencole SF, Callahan MV, Cannon JG, Lynch EA, Ye K, Poutsiaka DD, Vannier E, et al. Hematologic and immunomodulatory effects of an interleukin-1 receptor antagonist coinfusion during low-dose endotoxemia in healthy humans. Blood. 1993 Nov 15; 82(10):2985-90. PMID: 8219190.
    Citations: 15     Fields:    Translation:HumansCells
  109. Tilg H, Vannier E, Vachino G, Dinarello CA, Mier JW. Antiinflammatory properties of hepatic acute phase proteins: preferential induction of interleukin 1 (IL-1) receptor antagonist over IL-1 beta synthesis by human peripheral blood mononuclear cells. J Exp Med. 1993 Nov 01; 178(5):1629-36. PMID: 7693853.
    Citations: 50     Fields:    Translation:HumansCells
  110. Mier JW, Atkins MB. Mechanisms of action and toxicity of immunotherapy with cytokines. Curr Opin Oncol. 1993 Nov; 5(6):1067-72. PMID: 8305541.
    Citations: 1     Fields:    Translation:Humans
  111. Trehu EG, Isner JM, Mier JW, Karp DD, Atkins MB. Possible myocardial toxicity associated with interleukin-4 therapy. J Immunother Emphasis Tumor Immunol. 1993 Nov; 14(4):348-51. PMID: 8280718.
    Citations: 2     Fields:    Translation:Humans
  112. Tilg H, Shapiro L, Atkins MB, Dinarello CA, Mier JW. Induction of circulating and erythrocyte-bound IL-8 by IL-2 immunotherapy and suppression of its in vitro production by IL-1 receptor antagonist and soluble tumor necrosis factor receptor (p75) chimera. J Immunol. 1993 Sep 15; 151(6):3299-307. PMID: 8397255.
    Citations: 7     Fields:    Translation:HumansCells
  113. Tilg H, Pape D, Trehu E, Shapiro L, Atkins MB, Dinarello CA, Mier JW. A method for the detection of erythrocyte-bound interleukin-8 in humans during interleukin-1 immunotherapy. J Immunol Methods. 1993 Aug 09; 163(2):253-8. PMID: 8354894.
    Citations: 6     Fields:    Translation:HumansCellsCTClinical Trials
  114. Granowitz EV, Porat R, Mier JW, Orencole SF, Kaplanski G, Lynch EA, Ye K, Vannier E, Wolff SM, Dinarello CA. Intravenous endotoxin suppresses the cytokine response of peripheral blood mononuclear cells of healthy humans. J Immunol. 1993 Aug 01; 151(3):1637-45. PMID: 7687636.
    Citations: 34     Fields:    Translation:HumansCells
  115. Tilg H, Mier JW, Vogel W, Aulitzky WE, Wiedermann CJ, Vannier E, Huber C, Dinarello CA. Induction of circulating IL-1 receptor antagonist by IFN treatment. J Immunol. 1993 May 15; 150(10):4687-92. PMID: 8482853.
    Citations: 15     Fields:    Translation:HumansCTClinical Trials
  116. Atkins MB, Sparano J, Fisher RI, Weiss GR, Margolin KA, Fink KI, Rubinstein L, Louie A, Mier JW, Gucalp R, et al. Randomized phase II trial of high-dose interleukin-2 either alone or in combination with interferon alfa-2b in advanced renal cell carcinoma. J Clin Oncol. 1993 Apr; 11(4):661-70. PMID: 8478661.
    Citations: 29     Fields:    Translation:HumansCTClinical Trials
  117. Numerof RP, Sipe JD, Trehu EG, Dinarello CA, Mier JW. Suppression of IL-2-induced SAA gene expression in mice by the administration of an IL-1 receptor antagonist. Cytokine. 1992 Nov; 4(6):555-60. PMID: 1292638.
    Citations:    Fields:    Translation:Animals
  118. Atkins MB, Vachino G, Tilg HJ, Karp DD, Robert NJ, Kappler K, Mier JW. Phase I evaluation of thrice-daily intravenous bolus interleukin-4 in patients with refractory malignancy. J Clin Oncol. 1992 Nov; 10(11):1802-9. PMID: 1403061.
    Citations: 11     Fields:    Translation:HumansCellsCTClinical Trials
  119. Granowitz EV, Porat R, Mier JW, Pribble JP, Stiles DM, Bloedow DC, Catalano MA, Wolff SM, Dinarello CA. Pharmacokinetics, safety and immunomodulatory effects of human recombinant interleukin-1 receptor antagonist in healthy humans. Cytokine. 1992 Sep; 4(5):353-60. PMID: 1420996.
    Citations: 39     Fields:    Translation:HumansCTClinical Trials
  120. Massarotti EM, Liu NY, Mier J, Atkins MB. Chronic inflammatory arthritis after treatment with high-dose interleukin-2 for malignancy. Am J Med. 1992 Jun; 92(6):693-7. PMID: 1605152.
    Citations: 7     Fields:    Translation:Humans
  121. Sauter NP, Atkins MB, Mier JW, Lechan RM. Transient thyrotoxicosis and persistent hypothyroidism due to acute autoimmune thyroiditis after interleukin-2 and interferon-alpha therapy for metastatic carcinoma: a case report. Am J Med. 1992 Apr; 92(4):441-4. PMID: 1558092.
    Citations: 7     Fields:    Translation:Humans
  122. Vogelzang PJ, Bloom SM, Mier JW, Atkins MB. Chest roentgenographic abnormalities in IL-2 recipients. Incidence and correlation with clinical parameters. Chest. 1992 Mar; 101(3):746-52. PMID: 1541142.
    Citations: 3     Fields:    Translation:HumansCells
  123. Vachino G, Gelfand JA, Atkins MB, Tamerius JD, Demchak P, Mier JW. Complement activation in cancer patients undergoing immunotherapy with interleukin-2 (IL-2): binding of complement and C-reactive protein by IL-2-activated lymphocytes. Blood. 1991 Nov 15; 78(10):2505-13. PMID: 1824247.
    Citations: 16     Fields:    Translation:HumansCells
  124. Demchak PA, Mier JW, Robert NJ, O'Brien K, Gould JA, Atkins MB. Interleukin-2 and high-dose cisplatin in patients with metastatic melanoma: a pilot study. J Clin Oncol. 1991 Oct; 9(10):1821-30. PMID: 1655988.
    Citations: 8     Fields:    Translation:Humans
  125. Swack JA, Mier JW, Romain PL, Hull SR, Rudd CE. Biosynthesis and post-translational modification of CD6, a T cell signal-transducing molecule. J Biol Chem. 1991 Apr 15; 266(11):7137-43. PMID: 2016320.
    Citations: 10     Fields:    Translation:HumansCells
  126. Dutcher JP, Gaynor ER, Boldt DH, Doroshow JH, Bar MH, Sznol M, Mier J, Sparano J, Fisher RI, Weiss G, et al. A phase II study of high-dose continuous infusion interleukin-2 with lymphokine-activated killer cells in patients with metastatic melanoma. J Clin Oncol. 1991 Apr; 9(4):641-8. PMID: 2066760.
    Citations: 7     Fields:    Translation:HumansCellsCTClinical Trials
  127. Sznol M, Mier JW, Sparano J, Gaynor ER, Weiss GR, Margolin KA, Bar MH, Hawkins MJ, Atkins MB, Dutcher JP, et al. A phase I study of high-dose interleukin-2 in combination with interferon-alpha 2b. J Biol Response Mod. 1990 Dec; 9(6):529-37. PMID: 2074439.
    Citations: 3     Fields:    Translation:HumansCTClinical Trials
  128. Mier JW, Vachino G, Klempner MS, Aronson FR, Noring R, Smith S, Brandon EP, Laird W, Atkins MB. Inhibition of interleukin-2-induced tumor necrosis factor release by dexamethasone: prevention of an acquired neutrophil chemotaxis defect and differential suppression of interleukin-2-associated side effects. Blood. 1990 Nov 15; 76(10):1933-40. PMID: 2242421.
    Citations: 19     Fields:    Translation:HumansCellsCTClinical Trials
  129. Numerof RP, Kotik AN, Dinarello CA, Mier JW. Pro-interleukin-1 beta production by a subpopulation of human T cells, but not NK cells, in response to interleukin-2. Cell Immunol. 1990 Oct 01; 130(1):118-28. PMID: 2144468.
    Citations: 3     Fields:    Translation:HumansCells
  130. Parkinson DR, Fisher RI, Rayner AA, Paietta E, Margolin KA, Weiss GR, Mier JW, Sznol M, Gaynor ER, Bar MH, et al. Therapy of renal cell carcinoma with interleukin-2 and lymphokine-activated killer cells: phase II experience with a hybrid bolus and continuous infusion interleukin-2 regimen. J Clin Oncol. 1990 Oct; 8(10):1630-6. PMID: 2213100.
    Citations: 8     Fields:    Translation:HumansCellsCTClinical Trials
  131. Tatro JB, Atkins M, Mier JW, Hardarson S, Wolfe H, Smith T, Entwistle ML, Reichlin S. Melanotropin receptors demonstrated in situ in human melanoma. J Clin Invest. 1990 Jun; 85(6):1825-32. PMID: 2347915.
    Citations: 12     Fields:    Translation:Humans
  132. Klempner MS, Noring R, Mier JW, Atkins MB. An acquired chemotactic defect in neutrophils from patients receiving interleukin-2 immunotherapy. N Engl J Med. 1990 Apr 05; 322(14):959-65. PMID: 2156163.
    Citations: 26     Fields:    Translation:HumansCells
  133. Bergstrom RW, Atkins MB, Mier JW, Palmer JP. Augmentation of insulin autoantibodies following interleukin-2 and lymphokine activated killer cell therapy. J Clin Lab Immunol. 1990 Apr; 31(4):189-93. PMID: 1967063.
    Citations:    Fields:    Translation:HumansCells
  134. Mier JW, Brandon EP, Libby P, Janicka MW, Aronson FR. Activated endothelial cells resist lymphokine-activated killer cell-mediated injury. Possible role of induced cytokines in limiting capillary leak during IL-2 therapy. J Immunol. 1989 Oct 01; 143(7):2407-14. PMID: 2528594.
    Citations: 5     Fields:    Translation:HumansCells
  135. Ryan T, Atkins MB, Mier JW, Berkman EM. Lymphokine-activated killer cell generation and recovery. Comparison of an automated cell processing device and a manual procedure. Transfusion. 1989 Jul-Aug; 29(6):491-5. PMID: 2787549.
    Citations:    Fields:    Translation:HumansCells
  136. Numerof RP, Aronson FR, Mier JW. IL-2 stimulates the production of IL-1 alpha and IL-1 beta by human peripheral blood mononuclear cells. J Immunol. 1988 Dec 15; 141(12):4250-7. PMID: 3143761.
    Citations: 20     Fields:    Translation:HumansCells
  137. Mier JW, Vachino G, van der Meer JW, Numerof RP, Adams S, Cannon JG, Bernheim HA, Atkins MB, Parkinson DR, Dinarello CA. Induction of circulating tumor necrosis factor (TNF alpha) as the mechanism for the febrile response to interleukin-2 (IL-2) in cancer patients. J Clin Immunol. 1988 Nov; 8(6):426-36. PMID: 3265420.
    Citations: 44     Fields:    Translation:HumansAnimalsCells
  138. Boldt DH, Mills BJ, Gemlo BT, Holden H, Mier J, Paietta E, McMannis JD, Escobedo LV, Sniecinski I, Rayner AA, et al. Laboratory correlates of adoptive immunotherapy with recombinant interleukin-2 and lymphokine-activated killer cells in humans. Cancer Res. 1988 Aug 01; 48(15):4409-16. PMID: 3260537.
    Citations: 17     Fields:    Translation:HumansCells
  139. Aronson FR, Libby P, Brandon EP, Janicka MW, Mier JW. IL-2 rapidly induces natural killer cell adhesion to human endothelial cells. A potential mechanism for endothelial injury. J Immunol. 1988 Jul 01; 141(1):158-63. PMID: 3259966.
    Citations: 16     Fields:    Translation:HumansCells
  140. Atkins MB, Mier JW, Parkinson DR, Gould JA, Berkman EM, Kaplan MM. Hypothyroidism after treatment with interleukin-2 and lymphokine-activated killer cells. N Engl J Med. 1988 Jun 16; 318(24):1557-63. PMID: 3259674.
    Citations: 56     Fields:    Translation:HumansCells
  141. Fisher RI, Coltman CA, Doroshow JH, Rayner AA, Hawkins MJ, Mier JW, Wiernik P, McMannis JD, Weiss GR, Margolin KA, et al. Metastatic renal cancer treated with interleukin-2 and lymphokine-activated killer cells. A phase II clinical trial. Ann Intern Med. 1988 Apr; 108(4):518-23. PMID: 3258138.
    Citations: 55     Fields:    Translation:HumansCells
  142. Mier JW, Aronson FR, Numerof RP, Vachino G, Atkins MB. Toxicity of immunotherapy with interleukin-2 and lymphokine-activated killer cells. Pathol Immunopathol Res. 1988; 7(6):459-76. PMID: 2976936.
    Citations: 6     Fields:    Translation:HumansCellsCTClinical Trials
  143. Dainiak N, Najman A, Kreczko S, Baillou C, Mier J, Feldman L, Gorin NC, Duhamel G. B-lymphocytes as a source of cell surface growth-promoting factors for hematopoietic progenitors. Exp Hematol. 1987 Nov; 15(10):1086-96. PMID: 3499338.
    Citations: 2     Fields:    Translation:HumansCells
  144. Mier JW, Dinarello CA, Atkins MB, Punsal PI, Perlmutter DH. Regulation of hepatic acute phase protein synthesis by products of interleukin 2 (IL 2)-stimulated human peripheral blood mononuclear cells. J Immunol. 1987 Aug 15; 139(4):1268-72. PMID: 2440951.
    Citations: 6     Fields:    Translation:HumansAnimalsCells
  145. Aronson FR, Dempsey RA, Allegretta M, André-Schwartz J, Poldre PA, Hillyer CD, Parkinson DR, Rudders RA, Schwartz RS, Mier JW. Malignant granular lymphoproliferation after Epstein-Barr virus infection: partial immunologic reconstitution with interleukin-2. Am J Hematol. 1987 Aug; 25(4):427-39. PMID: 3039837.
    Citations: 3     Fields:    Translation:HumansCells
  146. Dinarello CA, Dempsey RA, Allegretta M, LoPreste G, Dainiak N, Parkinson DR, Mier JW. Inhibitory effects of elevated temperature on human cytokine production and natural killer activity. Cancer Res. 1986 Dec; 46(12 Pt 1):6236-41. PMID: 2430693.
    Citations: 10     Fields:    Translation:HumansCells
  147. Allegretta M, Atkins MB, Dempsey RA, Bradley EC, Konrad MW, Childs A, Wolfe SN, Mier JW. The development of anti-interleukin-2 antibodies in patients treated with recombinant human interleukin-2 (IL-2). J Clin Immunol. 1986 Nov; 6(6):481-90. PMID: 3491089.
    Citations: 4     Fields:    Translation:Humans
  148. Atkins MB, Gould JA, Allegretta M, Li JJ, Dempsey RA, Rudders RA, Parkinson DR, Reichlin S, Mier JW. Phase I evaluation of recombinant interleukin-2 in patients with advanced malignant disease. J Clin Oncol. 1986 Sep; 4(9):1380-91. PMID: 3489080.
    Citations: 27     Fields:    Translation:HumansCells
  149. Dinarello CA, Cannon JG, Mier JW, Bernheim HA, LoPreste G, Lynn DL, Love RN, Webb AC, Auron PE, Reuben RC, et al. Multiple biological activities of human recombinant interleukin 1. J Clin Invest. 1986 Jun; 77(6):1734-9. PMID: 3519678.
    Citations: 63     Fields:    Translation:HumansAnimalsCells
  150. Dinarello CA, Mier JW. Interleukins. Annu Rev Med. 1986; 37:173-8. PMID: 3518604.
    Citations: 17     Fields:    Translation:HumansAnimalsCells
  151. Bradley EC, Catino JJ, Issell BF, Poiesz B, Hustad JM, Dalton T, Allegretta M, Mier J. Cell-mediated inhibition of tumor colony formation in agarose by resting and interleukin 2-stimulated human lymphocytes. Cancer Res. 1985 Apr; 45(4):1464-8. PMID: 3872166.
    Citations: 2     Fields:    Translation:HumansCells
  152. Mier JW, Souza LM, Allegretta M, Boone T, Bernheim HA, Dinarello CA. Dissimilarities between purified human interleukin-1 and recombinant human interleukin-2 in the induction of fever, brain prostaglandin, and acute-phase protein synthesis. J Biol Response Mod. 1985 Feb; 4(1):35-45. PMID: 3872345.
    Citations: 4     Fields:    Translation:AnimalsCells
  153. Parkinson DR, Mier JW. T-lymphocyte malignancies: recent advances in the understanding of their biology, diagnosis and treatment. Clin Immunol Rev. 1983; 2(1):59-121. PMID: 6349892.
    Citations:    Fields:    Translation:HumansAnimalsCells
  154. Dempsey RA, Dinarello CA, Mier JW, Rosenwasser LJ, Allegretta M, Brown TE, Parkinson DR. The differential effects of human leukocyte pyrogen/lymphocyte-activating factor, T cell growth factor, and interferon on human natural killer activity. J Immunol. 1982 Dec; 129(6):2504-10. PMID: 6982930.
    Citations: 35     Fields:    Translation:HumansCells
  155. Mier JW, Gallo RC. The purification and properties of human T cell growth factor. J Immunol. 1982 Mar; 128(3):1122-7. PMID: 6976987.
    Citations: 14     Fields:    Translation:Humans
  156. Reiss CS, Hemler ME, Englehard VH, Mier JW, Strominger JL, Burakoff SJ. Development and characterization of allospecific long-term human cytolytic T-cell lines. Proc Natl Acad Sci U S A. 1980 Sep; 77(9):5432-6. PMID: 6968913.
    Citations: 6     Fields:    Translation:HumansAnimalsCells
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact feedbackcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Mier's Networks
Click the
buttons for more information and interactive visualizations!
Concepts (615)
Co-Authors (50)
Similar People (60)
Same Department 
Physical Neighbors
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.